Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We enclose herewith the transcript of the 'Q4 FY2022 Earnings Conference Call' which was hosted by the Company on Friday, 13th May, 2022. The said transcript shall also be made available on the website of the Company. Kindly take the same on record. Q4FY22 Quarterly Result Announced for Alkem Laboratories Ltd.
Pharmaceuticals firm Alkem Laboratories declares Q4FY22 result: Key highlights of Q4FY22 financial performance: Total Revenue from Operations was Rs 24,839 million, YoY growth of 13.3%. India sales were Rs 17,187 million, YoY growth of 16.7% International sales were Rs 7,411 million, YoY growth of 7.3% Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 3,372 million, resulting in EBITDA margin of 13.6% vs. 13.3% in Q4FY21. EBITDA grew by 15.8% YoY R&D; expenses for the quarter was Rs 1,634 million, or 6.6% of total revenue from operations compared to Rs 1,408 million in Q4FY21 at 6.4% of total revenue from operations Profit before tax (PBT) was Rs 2,427 million, a decline of 6.0% compared to Q4FY21. Exceptional Item of Rs 150 million debit was on account of fair value of an investment Net Profit (after Minority Interest) was Rs 1,076 million, YoY decline of 55.2%. Commenting on the results, Sandeep Singh, Managing Director, Alkem said, "FY22 was a mixed bag for the Company as our India business did well helped by COVID-19 tailwinds, while our US business faced significant pricing pressure. We forayed in the Indian respiratory segment with the launch of Pulmocare division which received an encouraging response. Our biotech subsidiary Enzene also made good progress with product launches in India and signing multiple product out-licensing deals. Going forward, while we are positive about our growth prospects given the levers we have built over the years, navigating the inflationary pressures of high raw material prices and increased freight rates, would be a key challenge for the Company." Result PDF
Earnings Call for Q4FY22 of Alkem Laboratories
Conference Call with Alkem Laboratories Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the 'Q4FY22 and FY22 Earnings Conference Call' is available on the website of the Company. Kindly take the same on records. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that MHRA had conducted an online inspection at the Company's Bioequivalence Center located at Taloja, Maharashtra from 31st January, 2022 to 4th February, 2022 and 08th February, 2022 to 10th February, 2022. As per the Good Clinical Practice (GCP) Inspection Statement dated 12th May, 2022, there were no critical or major observations identified and the said inspection stands closed. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Change in Directorate
The Board of Directors at its meeting held today i.e. 13th May, 2022, has, inter alia based on recommendation of Nomination and Remuneration Committee, Audit Committee and subject to approval of shareholders at the ensuing Annual General Meeting, approved the re-appointment of Mr. Sandeep Singh, as a Managing Director of the Company for the term of five (5) consecutive years with effect from 17th October, 2022 upto 16th October, 2027. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Closure of Trading Window
We refer to our earlier communication dated 28th March, 2022 regarding closure of trading window (for the purpose of financial results for the quarter and year ended 31st March, 2022) starting from 30th March, 2022 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and year ended 31st March, 2022 are communicated to the Stock Exchanges. The Financial Results of the Company for the quarter and year ended 31st March, 2022 having been communicated to the Stock Exchanges, today i.e. 13th May, 2022, the trading window shall open on 16th May, 2022. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q4FY22 and FY22 earnings and business updates and the same will be uploaded on the website of the Company. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Corporate Action - Fixes Record Date For Payment Of Dividend And Cut-Off Date For Annual General Meeting
The Board of Directors at its meeting held today i.e. 13th May, 2022, has, inter alia fixed 10th August, 2022 as the record date for the payment of final dividend and 18th August, 2022 as the Cut-off date for the purpose of the Annual General Meeting. The dividend, if declared by the shareholders, shall be paid on and from 30th August, 2022. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Corporate Action-Board approves Dividend
The Board of Directors at its meeting held today i.e. 13th May, 2022, has, inter alia: 1. recommended a final dividend of Rs. 4/- per equity share of Rs. 2/- each for the financial year ended 31st March, 2022, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. 2. fixed that the 48th Annual General Meeting of the Company shall be held on 25th August, 2022 and the cut-off date for the purpose of the said Annual General Meeting has been fixed as 18th August, 2022. 3. fixed 10th August, 2022 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 30th August, 2022. Kindly take the same on record.